An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Condition: Psoriasis Interventions: Biological: Secukinumab 300 mg; Other: Placebo Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Psoriasis | Psoriatic Arthritis | Research | Rheumatology | Study | Ultrasound